Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of QVM149 in Japanese Patients With Asthma
NCT03100825Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2017
- Primary completion
- Sep 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate in asthma, sponsored by Novartis. Primary endpoints: Treatment Emergent Adverse Events at 52 weeks and Serious Adverse Events at 52 weeks. Started Apr 2017; status: completed.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoate
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03100825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03100825.